Nestle SA, the world's biggest food and drink company, is beginning commercial talks with Australian pharmaceutical company Phosphagenics Ltd. to use one of its products for the treatment and prevention of metabolic syndrome.
The move underlines the Swiss company's determination to increase its focus on health foods, after its announcement last month that it will buy the medical nutrition unit of pharmaceutical giant Novartis for US$2.5 billion (Ђ1.88 billion).
Nestle Nutrition exercised its option under an existing commercial agreement to use Phospha-E for the treatment and prevention of metabolic syndrome, Phosphagenics said in a statement Friday, reports AP.
Metabolic syndrome is characterized by a variety of symptoms including abdominal obesity and elevated blood pressure.
The discovery of the submarine has unveiled a few "inconsistencies." For example, how can one explain the fact that the sub was found where it needed to be searched for from the start?
This problem is not limited to the situation with the "whale prison" in Russia's Far East, because many people buy tickets to go to oceanariums and turn a blind eye to the problem